Market Overview

Karyopharm Therapeutics Presents Promising Selinexor Data at ASH

Karyopharm Therapeutics (Nasdaq: KPTI) today announced the oral presentation of clinical data from an ongoing Phase 1 clinical trial of its lead oral SINE compound, Selinexor (KPT-330), in patients with relapsed and/or refractory non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) at the 2013 American Society of Hematology (ASH) Annual Meeting and Exposition being held December 7-10, 2013 in New Orleans, LA. The data indicate that, as of December 4, 2013, first-in-class oral Selinexor showed preliminary evidence of anti-cancer activity as a single agent in the majority of heavily pretreated relapsed and/or refractory NHL and CLL patients in the study cohort with progressive disease on study entry. In these NHL and CLL patients, Selinexor induced low levels of severe (Grade 3/4) adverse events, and several of these patients have remained on study with Selinexor as their only anti-cancer treatment for more than 6-12 months.

"We believe the data presented at ASH further demonstrate the potential of

See full press release

Posted-In: News Guidance Management Global


Most Popular

Related Articles (KPTI)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free